Key result
Trimetazidine demonstrated a regulatory effect on serum and platelet levels of 5-HT and SERT in rat models of myocardial infarction and depression.
Why the study?
Does trimetazidine alter serum and platelet levels of serotonin and serotonin transporter in rats with myocardial infarction and depression?
RCT (n=100)
Randomly divided
Does trimetazidine alter serum and platelet levels of serotonin and serotonin transporter in rats with myocardial infarction and depression?
p-value: p=>0.05
In a rat model, trimetazidine regulates serotonin and serotonin transporter levels, suggesting potential therapeutic benefits in myocardial infarction and comorbid depression.
Does not support clinical use in post-MI depression; hypothesis-generating for serotonin modulation in animal models.
BACKGROUND: Trimetazidine is an anti-ischemic drug that can inhibit platelet aggregation and regulate serotonin (5-hydroxytryptamine [5-HT]) release. The purpose of this study was to investigate the therapeutic effects of trimetazidine on 5-HT and serotonin transporter (SERT) expression in experimentally induced myocardial infarction (MI), depression, and MI + depression. MATERIALS AND METHODS: Eighty Sprague Dawley (SD) rats were randomly divided into a trimetazidine group and a saline group of 40 rats each. The trimetazidine group was given trimetazidine pretreatment for 4 weeks, while the saline group received saline for 4 weeks. Both groups were then subdivided into four subgroups (n=10), which were each subjected to a unique disease condition: sham surgery, MI, depression, or MI + depression. All rats were sacrificed 3 days thereafter, and serum and platelet levels of 5-HT and SERT were assessed. In addition, we experimented with trimetazidine posttreatment. Twenty SD rats underwent MI surgery, and were then randomly divided into a treatment and a saline group (n=10 each). For 4 weeks post-surgery, the trimetazidine group was given trimetazidine, while the saline group received saline. Serum and platelet levels of 5-HT and SERT were assessed. RESULTS: >0.05). CONCLUSION: Trimetazidine has a regulatory effect on 5-HT and SERT in the serum and platelets. Because of the downstream effects of this regulation on blood vessel function and myocardial protection, trimetazidine may be a therapeutic or preventive agent in several disease processes, including MI, depression, and the comorbidity between these two diseases. Further investigation, aimed at exploring the clinical potential of trimetazidine, is therefore warranted.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2018) conducted an RCT in Myocardial infarction and depression (n=100). Trimetazidine vs. Saline was evaluated on Serum and platelet levels of 5-HT and SERT (p=>0.05). Trimetazidine demonstrated a regulatory effect on serum and platelet levels of 5-HT and SERT in rat models of myocardial infarction and depression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: